NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Abmax back to previous page show list

Abmax

»
address: 7F, Building-2, 29# Shang Di Dong Road, HaiDian District, Beijing, P.R.China. 100085
contact: Mr Qing Wang
Tel:86-10-6298 0517
Fax:86-10-6297 7292
E-mail:minnie@antibodychina.com
www.antibody.com

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

AbMax Inc., a privately owned biotechnology company, was incorporated in Beijing, China, on August 31, 2006. AbMax occupied 4,600 square feet lab/office space with our own animal facility which meets the ALAAAC requirement. AbMax is located closely to TsinghuaUniversity, PekingUniversity and other key national research laboratories in China.

AbMax fully respects our clients' IP and keeps our clients' information in strict confidence.
 
AbMax's mission is to deliver monoclonal antibody services at the world's speed, with international standards, at the Chinese price. We at AbMax define clients' satisfaction as our success.
 
To speed up our client research, AbMax also offers One-stop Service including Recombinant Protein Expression, Gene Cloning & Synthesis, Antibody Conjugation, Antibody Imaging to meet all of our clients' needs.
 
Management
 
PRESIDENT AND CEO, Le Sun, PhD, has more than 14 years of biotechnology management experience in the US in business and product development, strategic planning, partnering, and licensing. He founded A&G Pharmaceutical Inc, in 2000. Under his leadership, within 18 months, A&G reached an agreement to co-develop a monoclonal antibody-based drug with MedImmunefor treatment of human breast cancer. An expert in the development and production of growth factors and antibodies, Dr. Sun has worked with a network of more than 200 preeminent cell biologists in the signal transduction field to commercialize their scientific discoveries.In 1990, he personally launched a monoclonal anti-phosphotyrosine antibody, clone 4G10, which revolutionized signal transduction research. Previously, Dr. Sun was Director of Research and Development at Upstate Biotechnology Inc., a market leader in the biotechnology supplies sector that supplies more than 1,000 research reagents for biomedical research. In that position, he also managed three R&D laboratories as well as the company's technology transfer office. His team introduced more than 600 new products to the cancer research market, including numerous kinases and phosphatases for high-throughput drug screening and luminex-based immunoassays for diagnostic applications. Prior to that, he served as Director of Production at Upstate Biotechnology. Dr. Sun received his PhD in biochemistry/cell biology from TsinghuaUniversity (Beijing). Dr. Sun spent two years as a postdoctoral fellow in Dr. David Barnes's lab at OregonStateUniversity, where he established primary cultures of zebrafish embryonic stem cells.
 
Vice President: Dr. Renying Zhu, M.D., was President of Biotech Incubator of Zhongguanchun Life Science Park, Beijing, China. VP of Union Pharmaceuticals LTD. Beijing, China. Lead the production and clinical trials of 4 protein drugs and obtained approvals from SFDA for two drugs in China. Prior to it, Dr. Zhu was Section Chief, Beijing 262 Hospital. He received his M.S. from Shanghai 2nd Military Medical Univ. in 1988 and M.D. from Shanghai 2nd Military Medical Univ. in 1983.
 
Director of Technical Support: Chunming Mao
 
Manager of Quality Control: Ms. Xiaolang Yang
 
Manager of Cell Culture: Mr. Shujun Ma
 
Manager of Molecular Biology: Mr. Jianting Ren
 
Services:
 
1. Custom mAb Service
2. Protein Expression

3. Gene Synthesis
4. Monoclonal antibody molecular cloning and chimerization
5. Monoclonal antibody Immunoconjugation
6. Monoclonal antibody isotope-labeling, radio-imaging and biodistribution
 
Custom mAb Service
 
They will be able to generate hybridoma producing monoclonal antibody specific to your antigen within 60 days if the antigen is available.
 
Material required: 0.5-1mg of the purified antigen (M.W.>30 kd) or pre-conjugated synthetic peptide (>12 a.a.) at a concentration of at least 0.2 mg/ml.
 
Procedure:
1. Day 0, start immunization of 3 mice
2. Day 20, check the tail bleeds ELISA and/or WB if the blots are provided by the client
3. Day 21, perform fusion
4. Day 40, screen hybridoma supernatants to identify the positive clones by ELISA
5. Day 44, perform 2nd ELISA and/or WB on ELISA-positive clones
6. Day 50, save up to 10 positively tested clones for each antigen target, and deliver 10 ml supernatant for each of these clones to the client for client's own confirmation
7. Day 55, grow up the hybridoma clones selected by client (up to five clones per antigen target)
8. Day 60, ship the hybridoma cells to the client
 
Total cost: $6,000
Supplemented Service:
Items Price
Peptide synthesis please inquire
Phosphor-peptide synthesis please inquire
Antigen conjugation $200
Antigen modification $200
Additional clone $125/clone
Mouse Ig typing $50/clone
BiaCore analysis $700/clone
Small ascites production $200 for 2~5 mg
Small Bioreactor production $300 for 2~5 mg
   
 
 
Recombinant Protein Expression
AbMax owns a patented Fc-tagged prokaryotic expression vector. Using our proprietary technology, we can generate recombinant protein antigen for monoclonal antibody generation within ONE month.

Material required: Plasmid or E. Coli strain containing the target gene and its sequence report.
Procedure:
1. PCR clone cDNA fragments encoding about 300 a.a. from the gene of interested
2. Perform DNA sequence analysis
3. Insert the cDNA fragment into our proprietary expression vector
4. Pilot production using E. Coli expression system
5. Purify the Fc-fusion for immunization
6. Remove the Fc tag by protease digestion. The resulting recombinant protein without Fc tag will be used for hybridoma screening. Purity>90%.
Total cost: $600
Gene Synthesis
To speed your discovery, we also offer a custom designed gene synthesis service. Now you can get the exact sequence you need without investing months in lab time. Just call us. We can help you design your synthetic genes (coding sequences) for a variety of applications.
Material required: the name of the gene and its accession number in the gene bank
Cost: <1000bp $1/bp, 1000-2500bp $1.3/bp
 
Monoclonal Antibody Molecular Cloning & Chimerization
We will quickly clone out the variable regions of the monoclonal antibody from the hybridoma you sent to us. The cloned variable regions will be inserted into a proprietary mammalian expression vector containing the constant regions of human IgG1 light chain and heavy chain. A transient expression using CHO-dhfr cells will be performed to confirm the expression of the human/mouse chimeric monoclonal antibody with the right specificity by ELISA if the antigen is provided.
Material required
Either one T-75 of live cells or a frozen vial of stock cells
 
Phase I Cloning of the variable regions of the mAb, Two Weeks, Promotion Price $2,000
  • Isolation of RNA from the hybridoma
  • RT-PCR
  • Cloning of the variable regions of the light chain and heavy chain using our proprietary primers by PCR
  • Ligation of the PCR products into T-vector
  • Sequencing 5 clones for each light chain and heavy chain
  • Reporting the sequence data
Phase II Chimerization, Promotion Price $15,000
  • Inserting the cloned variable regions into the proprietary expression vector containing the constant regions of HUMAN IgG1
  • Confirming the correct ligation by PCR
  • Transfecting the CHO-dhfr- cells or NS0/1 cells.
  • Cloning of the transfected cells
  • Collecting the culture media
  • Performing ELISA to test specificity against the antigen
  • Sending out the expression plasmid to the client.
Monoclonal Antibody Immunoconjugation
We will link two approved anti-tumor antibiotics to your purified monoclonal antibody using our proprietary conjugation method. The anti-tumor agent will remain bound to the monoclonal antibody and inactive but will be released and activated by reduction once the immunocomplex binds to the cell surface antigen and internalized.
 
1. Pilot Study
Material required
3~5 mg purified monoclonal antibody needed
Phase I Generation of antibody immunoconjugates, Promotion Price $20,000
  • Exchange the antibody buffer to the conjugation buffer
  • Activation of the antibody
  • Conjugation of the antibody to TWO different drugs at TWO different molar ratio
  • Purification of the immunoconjugates
  • Filter-sterilization
Phase II In vitro Bioassay Please inquire.
  • Seeding the cells in 96-well plate, up to THREE different cell lines
  • Adding the immunoconjugates at various concentrations.
  • Performing MTT assay on day 5.
  • Repeat the bioassay twice
2. Medium-size Production
Material required
5~10 mg purified monoclonal antibody needed
Phase I Generation of antibody immunoconjugates Promotion Price $3,000
  • Exchange the antibody buffer to the conjugation buffer
  • Activation of the antibody
  • Conjugation of the antibody to ONE drug at TWO different molar ratio
  • Purification of the immunoconjugates
  • Filter-sterilization
Phase II In vitro Bioassay Promotion Price $7,000
  • Seeding the cells in 96-well plate, up to THREE different cell lines
  • Adding the immunoconjugates at various conc.
  • Performing MTT assay on day 5.
  • Repeat the bioassay once
  • Sending out 2 mg immunoconjugate.
Phase III In vivo animal study Promotion Price $20,000
  • Innoculate 30 nude mice with the right number of tumor cells
  • Once the tumors reach 10 mm, 5 mice per group will be injected with various amount of immunoconjugate, naked antibody, unconjugated drug and buffer
  • Tumor size will be measured every 3 or 4 days
  • At the end of the test, the tumors will be removed and weighed individually.
  • Repeat the animal study twice.
 
Isotope-labeling, Radio-imaging and Bio-distribution Study
It is extremely important to find out the bio-distribution of the drug before moving into the next phase of drug development. We are proudly offering the service to label your drug with either 125-I or 111-In. Radio-imaging and bio-distribution will be performed.
Material required
One mg of purified antibody, protein or small molecular drug. Tumor cell line of interest if it is not commercially available.
Phase I Isotope-labeling and SPECT radio-imaging, Promotion Price $10,000
  • Establishment of tumors in 5 nude mice with tumor cells of interest
  • Labeling 0.2 mg antibody with 5 mci 125-I by the Iodogen method
  • Purification of the isotope-labeled antibody using PD-10 column
  • Determination of the labeling efficiency, purification yield, purity and specific activity
  • Confirming the biological activity by ELISA against tumor cells or purified antigen
  • IV-injecting isotope-labeled antibody into two of the nude mice bearing tumors
  • Performing SPECT imaging at 4 different time points (4, 24, 48, and 72 hr for full length mAb)
  • Sending out the results to the customers by email
Phase II Isotope-labeling and Bio-distribution, Promotion Price $30,000
  • Establishment of tumors in 25 nude mice with tumor cells of interest
  • Labeling 0.2 mg antibody with 5 mci 125-I by the Iodogen method
  • Purification of the isotope-labeled antibody using PD-10 column
  • Determination of the labeling efficiency, purification yield, purity and specific activity
  • Confirming the biological activity by ELISA against tumor cells or purified antigen
  • IV-injecting isotope-labeled antibody into 16 of the nude mice bearing tumors
  • Collecting 10 different organs plus blood from 4 of the mice at each time point. Total 4 time points (e.g. 4, 24, 48, 72 hr)
  • Reporting the data by email.
Phase III Isotope-labeling and Pharmacokenetics, Please inquire.
  • Labeling 0.2 mg antibody with 5 mci 125-I by the Iodogen method
  • Purification of the isotope-labeled antibody using PD-10 column
  • Determination of the labeling efficiency, purification yield, purity and specific activity
  • Confirming the biological activity by ELISA against tumor cells or purified antigen
  • IV-injecting isotope-labeled antibody mixed unlabeled antibody at the given dosages into 5 Balb/c mice
  • Collecting blood from the mice at 8 various time points (e.g. 0.5, 1, 2, 4, 8, 24, 48, 72 hr)
  • Reporting the data by email

 
 

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.